A new study published in the International Journal of Molecular Sciences indicated pretreating cells with CBD inhibited the expression of amyloid-beta proteins, thereby preventing the development of Alzheimer's disease. In the study, a team of Italian researchers led by Rosaliana Libro administered CBD to mesenchymal stem cells derived from gingiva (GMSCs) and found pretreating with CBD caused a downregulation in the genes linked to Alzheimer's. CBD also modified the genes involved in the production of beta-amyloid proteins. Libro explains, “In conclusion, this preliminary in vitro study has demonstrated that GMSCs preconditioned with CBD have better therapeutic potential compared to [control] GMSCs cells, and we believe that their transplantation in the early stage of [Alzheimer’s disease] may play a role in preventing or attenuating the disease onset."
This information has been provided by Medical Marijuana Inc. and approved by our Chief Medical Officer.